Drug Discovery World

DECEMBER 4, 2023

The investigational compound Elenagen is an experimental DNA therapy that consists of a circular piece of DNA called a plasmid that includes a gene for a human protein called p62/SQSTM1. Elenagen also reduced systemic chronic inflammation in the organism, which plays a detrimental role in many diseases, including cancer.

DNA 147

DNA Therapies Packaging Vaccine 147

Drug Discovery World

FEBRUARY 23, 2024

Efficacy was evaluated in the Phase III trial FLAURA2 in 557 patients with EGFR exon 19 deletion or exon 21 L858R mutation-positive la/mNSCLC and no prior systemic therapy for advanced disease. The post Combination therapy reduced risk of lung cancer progression by 38% appeared first on Drug Discovery World (DDW).

Therapies 130

Therapies FDA Trials Treatment 130

Drug Discovery World

MARCH 2, 2023

The Avacta Therapeutics Science Day brought together senior company scientists and international oncology experts to provide an overview of the current development of the company’s cancer drug pipeline and the latest innovations in targeted oncology.

Therapies 130

Therapies Treatment Trials Disease 130

Drug Discovery World

OCTOBER 31, 2023

Professor Andy Whiting and Dr Tony Lockett discuss how specific levels of a protein could be used to advance drug development in neurodegenerative diseases. These parameters aim to measure the progression of disease over time by looking at the functional or observable change in a patient.

Drug Development 147

Drug Development Disease Drugs Clinical Trials 147

Drug Discovery World

SEPTEMBER 16, 2022

A biologic therapy for very young children with moderate to severe eczema (or atopic dermatitis) has been shown to be safe and effective in an international trial. The therapy is already licensed in the UK for adults and children aged six to 18, and was approved by the FDA in June 2022 for use in younger children.

Therapies 130

Therapies Licensing Licensing Clinical Research 130

Drug Discovery World

JULY 19, 2023

Eli Lilly has announced positive results of the TRAILBLAZER-ALZ 2 Phase III study showing that donanemab significantly slowed cognitive and functional decline in people with early symptomatic Alzheimer’s disease.

Disease 130

Disease Trials Clinical Trials Therapies 130

Drug Discovery World

MAY 16, 2023

What are the global innovations in cell and gene therapy? What opportunities and challenges are emerging and can therapies get to market faster? Curbishley explains that as the wave of new therapies in development continues to increase, global pressures on manufacturing availability will become more acute.

Therapies 130

Therapies Clinical Trials Marketing Production 130

DrugBank

JUNE 13, 2024

Unlike traditional oral medications with limited bioavailability and potential for erratic absorption, IDDS function as internal drug repositories, delivering precise doses of medication directly at the site of action or into the systemic circulation via precisely adjusted release mechanisms. 

Therapies 76

Therapies Drugs DNA Engineering 76

Conversations in Drug Development Trends

JANUARY 24, 2024

Written By: Derek Ansel, MS, CCRA, Executive Director, Therapeutic Strategy Lead, Rare Disease Given that 80% of rare diseases have a genetic etiology, genetic implications should be addressed at the onset of a clinical program to support trial enrollment.

Trials 75

Trials Disease Clinical Trials Clinical Research 75

Drug Discovery World

JULY 14, 2022

Biotech company Actigen has moved closer to clinical trials for rare disease treatment for Hunter syndrome, following a pre-Investigational New Drug (IND) meeting with the US Food and Drug Administration (FDA). ? . It occurs primarily in males and current treatment options such as enzyme replacement therapy, only offer a partial solution.

Clinical Trials 130

Clinical Trials Trials Treatment Disease 130

Drug Discovery World

DECEMBER 1, 2023

The key drug discovery news this week focuses on experimental approaches to the treatment of some of the most challenging diseases, including a mathematical model that can simulate Alzheimer’s progression and using CRISPR gene editing to ‘shred’ tumours. Can a plant-based discovery pave the way for new drug treatments?

Therapies 130

Therapies Drugs International Disease 130

Drug Target Review

JUNE 3, 2024

How does COUR Pharmaceuticals’ immune-modifying nanoparticle platform differ from traditional approaches to treating immune-mediated diseases? Essentially, our CNPs reprogramme the immune system by restoring balance and returning the body to a homeostatic state, offering a precise approach to treating immune-mediated diseases.

Disease 49

Disease Pharmaceuticals Therapies Clinical Trials 49

Drug Discovery World

JANUARY 18, 2024

Poolbeg Pharma, a biopharmaceutical company focused on the development and commercialisation of medicines targeting diseases with a high unmet medical need, has announced promising in vivo results for POLB 001 in addressing cancer immunotherapy-induced cytokine release syndrome (CRS). million cases of cancer by 2030 1,2.

Treatment 162

Treatment Clinical Trials Immune Response Therapies 162

Drug Discovery World

AUGUST 2, 2023

Fifty percent of neuroblastoma patients have high-risk (HRNB) disease which has an overall survival of ~50% over five years. into induction therapy and additionally, within post-consolidation therapy, demonstrated outstanding patient outcomes with overall survival (OS) of 86.0% A novel Phase II trial incorporating Hu14.18

Licensing 246

Licensing Licensing Hospitals Therapies 246

Fierce BioTech

SEPTEMBER 11, 2023

Aligning cross-functional teams across the organization to ensure medical, marketing, and market access are all in lock-step is even more crucial when launching a therapy into a rare disease market. Click here to login. Listing Image HerspiegelConsulting_LogoListingNew_10262023.png On Demand Start Date Thu, 10/26/2023 - 11:00

Production 52

Production Disease FDA Approval International 52

Drug Discovery World

FEBRUARY 2, 2024

Sunday 4 February is World Cancer Day, an international awareness day led by the Union for International Cancer Control (UICC), so the round-up this week will focus on oncology, including the UK approval of a rare blood cancer drug and a novel production process for CAR-T therapies.

Pharmacokinetics 130

Pharmacokinetics International Clinical Trials Drugs 130

Drug Discovery World

AUGUST 26, 2022

A treatment for Monkeypox, spider venom for drug discovery and funding for international start-ups are some of the stories in this week’s news round-up. Bayer to advance Huntington’s Disease gene therapy trial . International start-ups receive funding from BioInnovation . Covid researchers launch Monkeypox study .

International 130

International Drugs Clinical Trials Treatment 130

Drug Discovery World

OCTOBER 13, 2023

The UK’s University of Oxford is taking the lead on two collaborative international projects to improve the response to new Covid-19 variants and contribute to future pandemic preparedness. The scientists say the tool can help inform the development of vaccines and therapies for SARS-CoV-2 and other rapidly mutating viruses.

Vaccine 264

Vaccine Virus Medical Schools Immune Response 264

Drug Discovery World

APRIL 25, 2023

University of California researchers have dosed the second participant in their clinical trial to identify a potential cure for HIV utilising CAR-T cell therapy. The trial is the first-in-human clinical study investigating the duo CAR-T cell therapy for the treatment of HIV. “We

Research 130

Research Clinical Trials Therapies Clinical Development 130

Drug Discovery World

NOVEMBER 3, 2023

News round-up for 30 October – 3 November by DDW Editor Reece Armstrong My news highlights this week feature a variety of exciting clinical trial results and launches that are examining therapies for much-needed disease areas, new drug approvals and even a space mission with a pharma twist.

Clinical Trials 130

Clinical Trials Drugs Trials Therapies 130

Drug Discovery World

JANUARY 5, 2024

The top stories: China’s NMPA okays maribavir for post-transplant cytomegalovirus Takeda’s Livtencity (maribavir) has been approved in China for the treatment of adult patients with post-hematopoietic stem cell transplant (HSCT) or solid organ transplant (SOT) cytomegalovirus (CMV) infection/disease.

International 130

International Drugs FDA Regulations 130

Drug Discovery World

MAY 6, 2024

A more established Amsterdam-based enterprise is gene therapy company uniQure, developer of etranacogene dezaparvovec, the first gene therapy for haemophilia B, which was approved for use in the US in November 2022 and in the EU in February 2023. This pedigree has attracted beneficial international collaborations.

Drugs 147

Drugs Molecular Biology Science Clinical Trials 147

Drug Discovery World

SEPTEMBER 16, 2022

A slightly quieter week for news in light of national events in the UK, but the vital work of the international drug discovery community goes on and new discoveries are being made all the time. . First biologic therapy for young children with severe eczema . FDA approves new first-line therapy for plaque psoriasis .

FDA Approval 130

FDA Approval Drugs FDA Clinical Trials 130

Drug Discovery World

JUNE 28, 2023

Takeda has revealed favourable interim results from its Phase III crossover trial evaluating the safety and efficacy of TAK-755 (recombinant ADAMTS13) replacement therapy for the prophylactic treatment of congenital thrombotic thrombocytopenic purpura (cTTP).

Trials 130

Trials Clinical Trials Therapies Drugs 130

The Pharma Data

MARCH 9, 2021

New data from 10 studies will be presented by Eli Lilly and Company (NYSE: LLY) at the upcoming virtual International Conference on Alzheimer’s & Parkinson Diseases 2021 (AD/PD 2021), March 9-14, 2021. vice president of Alzheimer’s disease development unit, Eli Lilly and Company.

Disease 40

Disease International Research Therapies 40

Drug Discovery World

MAY 30, 2024

Unlike existing anti-obesity therapies that compromise lean muscle mass, ATR-127 induces significant weight loss while preserving crucial lean body mass. Our vision is for a more holistic treatment for diabesity and steatohepatitis that not only treats the underlying cause of disease but also supports overall health and quality of life.”

Small Molecule 147

Small Molecule Treatment International Production 147

Drug Discovery World

DECEMBER 14, 2023

However, 50% of responding patients will relapse either due to evolution of CD19 negative disease or early loss of CAR T-cells so that only around 40% of patients are cured by the currently licensed CAR T-cell therapies. There is thus a clear unmet need to develop novel CAR T-cell products with improved efficacy.

Research 130

Research Clinical Trials Licensing Licensing 130

Drug Discovery World

JUNE 14, 2023

The International Society for Cellular Therapy (ISCT) is a global society of clinicians, regulators, technologists, and industry partners with a shared mission to drive the translation of all cell and gene (CGT) therapies for the benefit of patients worldwide. Autoimmune diseases include at least 80 disorders.

Therapies 130

Therapies Clinical Trials Disease International 130

The Pharma Data

JUNE 28, 2021

Food and Drug Administration (FDA) granted Breakthrough Therapy designation for donanemab, Eli Lilly and Company’s (NYSE: LLY) investigational antibody therapy for Alzheimer’s disease (AD). Dementia due to Alzheimer’s disease is the most common form of dementia, accounting for 60 to 80 percent of all cases 1.

Therapies 40

Therapies Disease Treatment FDA Approval 40

Vial

DECEMBER 11, 2023

Pathophysiological evidence links HCV infections to the risk of liver diseases such as hepatocellular carcinoma (HCC) and liver cirrhosis. Other inhibitors, currently in different stages of development (including clinical trials ), mainly target viral non-structural proteins or the internal ribosome entry site (IRES).

Clinical Research 52

Clinical Research Therapies Research Vaccine 52

FDA Law Blog: Drug Discovery

NOVEMBER 2, 2023

Lewis, Senior Regulatory Device & Biologics Expert — On October 20, 2023, FDA announced the availability of the final guidance authored by CBER titled “Voluntary Consensus Standards Recognition Program for Regenerative Medicine Therapies.” It finalized a draft guidance published in 2022.

Therapies 59

Therapies FDA Production Regulations 59

Drug Discovery World

JANUARY 27, 2023

Enhertu has been approved in the EU as the first HER2 directed therapy for patients with HER2 low metastatic breast cancer. The drug is approved as monotherapy for adult patients who have received prior chemotherapy in the metastatic setting or developed disease recurrence during or within six months of completing adjuvant chemotherapy.

Engineering 130

Engineering Drugs Therapies International 130

Drug Discovery World

DECEMBER 13, 2022

A novel, patient-tailored monoclonal antibody therapy has shown promise in treating moderate to severe atopic dermatitis. . Patients who participated in a clinical trial of rocatinlimab showed positive results while taking the drug and up to 20 weeks after stopping therapy, Mount Sinai researchers have reported in The Lancet. .

Treatment 130

Treatment Clinical Trials Laboratories Therapies 130

The Pharma Data

JULY 15, 2021

Challenge to Support an Innovative Solution That Addresses Disconnect in Perception of Psoriatic Disease Severity and Undertreatment Documented in Multinational UPLIFT Survey UPLIFT Data Presented at WPPAC 2021 Report Substantial Disease Burden for People Living With Psoriasis and Psoriatic Arthritis.

International 52

International Disease Treatment Science 52

Drug Discovery World

JUNE 12, 2023

The International Society for Cellular Therapy (ISCT) is a global society of clinicians, regulators, technologists, and industry partners with a shared mission to drive the translation of all cell and gene therapies for the benefit of patients worldwide. DDW’s Megan Thomas heard from attendees about key trends in the sector.

Therapies 130

Therapies International Regulations Production 130

Drug Discovery World

JUNE 16, 2023

The International Society for Cellular Therapy (ISCT) is a global society of clinicians, regulators, technologists, and industry partners with a shared mission to drive the translation of all cell and gene (CGT) therapies for the benefit of patients worldwide.

Therapies 130

Therapies Compliance Production International 130

Drug Discovery World

JUNE 15, 2023

The International Society for Cellular Therapy (ISCT) is a global society of clinicians, regulators, technologists, and industry partners with a shared mission to drive the translation of all cell and gene (CGT) therapies for the benefit of patients worldwide. Here, attendees weigh in on future regulatory changes.

Regulations 130

Regulations Therapies Production Clinical Trials 130